Epizyme says it’s excited by PhII data, but there’s plenty to fret about
Epizyme execs spent most of the day on Sunday making the case that their lead cancer drug tazemetostat just cleared an important milestone at an early point in a Phase II study, demonstrating an ability to shrink tumors in patients with non-Hodgkin lymphoma.
But analysts say that at this early stage of development, enthusiasm over signs of progress has to be tempered by the limited number of patients who have responded so far and caution over the biotech’s high-risk strategy to shoot for an accelerated approval. That cautionary tone helped drive down shares by 6% in early trading today.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.